SCHEMBL3765112

SCHEMBL3765112

CN(C(=O)OC(C)(C)C)c1cn[c]c(-c2ccccc2)c1C(=O)N1CCC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
USP30 Q70CQ3 4/20 0.35
GBA1 P04062 1/20 0.35
HPGDS O60760 2/20 0.34
BRD4 O60885 1/20 0.34
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
PAX8 Q06710 1/20 0.33
POLB P06746 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771096 0.97 KMT2A (0.38) CKS1BSKP1SKP2HTTSMN1; SMN2
SCHEMBL3754775 0.81 KMT2A (0.44) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3767247 0.79 CKS1B (0.41) CKS1BSKP1SKP2HTTSMN1; SMN2
SCHEMBL3755044 0.77 BRD9 (0.40) CKS1BSKP1SKP2HTTSMN1; SMN2
SCHEMBL3766617 0.76 BRD9 (0.40) CKS1BSKP1SKP2HTTSMN1; SMN2
SCHEMBL3760043 0.75 SMN1; SMN2 (0.44) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3764989 0.73 SMN1; SMN2 (0.44) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3751655 0.73 KMT2A (0.45) HTTSMN1; SMN2KMT2AMEN1HPGD
SCHEMBL3759178 0.73 SIGMAR1 (0.40) CKS1BSKP1SKP2GBA1HPGDS
SCHEMBL3752062 0.72 HPGD (0.47) HTTSMN1; SMN2KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA CKS1B 622/4885SKP1 433/4885SKP2 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.